PMID- 25722472
OWN - NLM
STAT- MEDLINE
DCOM- 20160325
LR  - 20181113
IS  - 2157-1422 (Electronic)
IS  - 2157-1422 (Linking)
VI  - 5
IP  - 7
DP  - 2015 Feb 26
TI  - Tuberculosis and HIV Coinfection.
PG  - a017871
LID - 10.1101/cshperspect.a017871 [doi]
LID - a017871
AB  - Tuberculosis (TB) and human immunodeficiency virus/acquired immunodeficiency 
      syndrome (HIV/AIDS) constitute the main burden of infectious disease in 
      resource-limited countries. In the individual host, the two pathogens, 
      Mycobacterium tuberculosis and HIV, potentiate one another, accelerating the 
      deterioration of immunological functions. In high-burden settings, HIV 
      coinfection is the most important risk factor for developing active TB, which 
      increases the susceptibility to primary infection or reinfection and also the 
      risk of TB reactivation for patients with latent TB. M. tuberculosis infection 
      also has a negative impact on the immune response to HIV, accelerating the 
      progression from HIV infection to AIDS. The clinical management of HIV-associated 
      TB includes the integration of effective anti-TB treatment, use of concurrent 
      antiretroviral therapy (ART), prevention of HIV-related comorbidities, management 
      of drug cytotoxicity, and prevention/treatment of immune reconstitution 
      inflammatory syndrome (IRIS).
CI  - Copyright (c) 2015 Cold Spring Harbor Laboratory Press; all rights reserved.
FAU - Bruchfeld, Judith
AU  - Bruchfeld J
AD  - Unit of Infectious Diseases, Institution of Medicine Solna, Karolinska Institutet 
      and Karolinska University Hospital, Stockholm SE-171 77, Sweden.
FAU - Correia-Neves, Margarida
AU  - Correia-Neves M
AD  - Life and Health Sciences Research Institute (ICVS), School of Health Sciences, 
      University of Minho, Braga 4710-057, Portugal ICVS/3B's, PT Government Associate 
      Laboratory, Braga/Guimaraes 4710-057, Portugal.
FAU - Kallenius, Gunilla
AU  - Kallenius G
AD  - Karolinska Institutet, Department of Clinical Science and Education, Stockholm 
      SE-118 83, Sweden.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20150226
PL  - United States
TA  - Cold Spring Harb Perspect Med
JT  - Cold Spring Harbor perspectives in medicine
JID - 101571139
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Anti-HIV Agents/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - Antitubercular Agents/*therapeutic use
MH  - Coinfection/*drug therapy/*epidemiology
MH  - Disease Susceptibility
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/drug therapy
MH  - Mycobacterium tuberculosis
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Tuberculosis/*drug therapy
PMC - PMC4484961
EDAT- 2015/02/28 06:00
MHDA- 2016/03/26 06:00
PMCR- 2017/07/01
CRDT- 2015/02/28 06:00
PHST- 2015/02/28 06:00 [entrez]
PHST- 2015/02/28 06:00 [pubmed]
PHST- 2016/03/26 06:00 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - cshperspect.a017871 [pii]
AID - a017871 [pii]
AID - 10.1101/cshperspect.a017871 [doi]
PST - epublish
SO  - Cold Spring Harb Perspect Med. 2015 Feb 26;5(7):a017871. doi: 
      10.1101/cshperspect.a017871.